维普中文期刊产品整合服务

Distinctive serotypes of SARS-related coronaviruses defined by convalescent sera from unvaccinated individuals

查看全文 作  者:Chee Wah [1]Tan;Feng [1]Zhu;Wan Ni [1]Chia;#Barnaby [2,3,4]EYoung;Aileen Ying Yan [1]Yeoh;Thomas [5,6]Althaus;Chee Fu [4,7,8]Yung;Wee Chee [1]Yap;Beng Lee [1]Lim;Mark I-C [2,3]Chen;Jinyan [1]Zhang;Yun Yan [1]Mah;Eric [6]Voiglio;Alex [9]Sigal;Jianxin [10]Huo;Shengli [10,11]Xu;Yee Joo [12,13]Tan;Kong-Peng [10,12,14]Lam;David [2,3,4,12]Lye;Lin-Fa [1,15]Wang 高影响力作者 机构地区:[1]Programme in Emerging Infectious Diseases,Duke-NUS Medical School,Singapore;[2]National Center of Infectious Diseases,Singapore;[3]Tan Tock Seng Hospital,Singapore;[4]Lee Kong Chian School of Medicine,Nanyang Technology University,Singapore;[5]Centre Scientifique de Monaco,Monaco;[6]Direction de I’Action Sanitaire de Monaco,Monaco;[7]Infectious Disease Service,Department of Pediatrics,KK Women’s and Children’s Hospital,Singapore;[8]Duke-NUS Medical School,Singapore;[9]African Health Research Institute,Durban,South Africa;[10]Singapore Immunology Network,Agency for Science,Technology and Research,Singapore;[11]Department of Physiology,Yong Loo Lin School of Medicine,National University of Singapore,Singapore;[12]Department of Microbiology and Immunology,Yong Loo Lin School of Medicine,National University of Singapore,Singapore;[13]Infectious Diseases Translational Research;[14]Programme,National University of Singapore,Singapore 14School of Biological Sciences,Nanyang Technological University,Singapore;[15]Singhealth Duke-NUS Global Health Institute,Singapore高影响力机构 出  处:《hLife》索引2023年第1卷第1期,共9页高影响力期刊 基  金:supported in part by grants from the National Medical Research Council(COVID19RF-001,COVID19RF-003,COVID19RF-0008,COVID19RF-0014,COVID19RF-0018,COVID19RF3-0060,MOH-000535/MOH-OFYIRG19nov-0002 and MOH-000505-02);SingHealth Duke-NUS Academic Medicine COVID-19 Rapid Response Research Grant(AM/COV001/2020);Collaborative Research Fund(C2103-20GF);Wellcome COVID-19 Grant on Understanding the Biological Significance SARS-CoV-2 Variants(226120/Z/22/Z);National Institute of Health NIAID(R01AI163118 and 5U01AI151797);National Public Health COVID Program of the Government of Monaco. 摘  要:Multiple Omicron sub-lineages have emerged,with Omicron XBB and XBB.1.5 subvariants becoming the dominant variants globally at the time of this study.The key feature of new variants is their ability to escape humoral immunity despite the fact that there are limited genetic changes from their preceding variants.This raises the question of whether Omicron should be regarded as a separate serotype from viruses serologically clustered with the ancestral severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)virus.Here,we present cross-neutralization data based on a pseudovirus neutralization test using convalescent sera from naïve individuals who had recovered from primary infection by SARS-CoV-1 and SARS-CoV-2 strains/variants including the ancestral virus and variants Beta,Delta,Omicron BA.1,Omicron BA.2 and Omicron BA.5.The results revealed no significant cross-neutralization in any of the three-way testing for SARS-CoV-1,ancestral SARS-CoV-2 and SARS-CoV-2 Omicron subvariants.The data argue for the assignment of three distinct serotypes for the currently known human-infecting SARS-related coronaviruses. 关 键 词:SARS-CoV-2 SARS-CoV-1 SEROTYPE Omicron primary infection convalescent sera
相关文献

参考文献(22)

引证文献(7)

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1 渝公网安备 50019002500403号 违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费